Nurix Therapeutics Inc. (NRIX)
NASDAQ: NRIX
· Real-Time Price · USD
11.96
0.47 (4.09%)
At close: Jun 23, 2025, 3:59 PM
12.70
6.23%
Pre-market: Jun 24, 2025, 05:47 AM EDT
4.09% (1D)
| Bid | 11.31 |
| Market Cap | 911.4M |
| Revenue (ttm) | 56.42M |
| Net Income (ttm) | -208.4M |
| EPS (ttm) | -2.79 |
| PE Ratio (ttm) | -4.28 |
| Forward PE | -3.58 |
| Analyst | Buy |
| Ask | 12.71 |
| Volume | 449,312 |
| Avg. Volume (20D) | 966,046 |
| Open | 11.47 |
| Previous Close | 11.49 |
| Day's Range | 11.32 - 11.97 |
| 52-Week Range | 8.18 - 29.56 |
| Beta | 2.16 |
About NRIX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol NRIX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for NRIX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Nurix Therapeutics Inc. is scheduled to release its earnings on Jul 10, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago
+14.21%
Nurix Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
6 months ago
+6.78%
Nurix Therapeutics shares are trading higher after BTIG initiated coverage on the stock with a Buy rating and announced a price target of $35.
2 months ago · seekingalpha.com
Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big PotentialFDA IND clearance given for BTK degrader GS-6791, targeting inflammatory disorders, allowing Nurix Therapeutics, Inc. to receive a $5 million milestone payment from Gilead Sciences. Nurix has earned $...
